ClinicalTrials.gg
RecruitingNCT07510919SENSTROKEUpdated Nov 17, 2026

CGM in Acute Ischemic Stroke

An interventional study of Continuous Glucose Monitoring and Point-of-Care Testing in Acute Ischemic Stroke, Diabetes (DM) and Diabetes Type 2, sponsored by Isala. Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Isala · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 17, 2026Now RecruitingFirst site in Netherlands+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in Ischemic Stroke with a site in Netherlands — 14 open to participants now, 17 under way, 2 of them phase 3. Ischemic Stroke · Netherlands.

Planned enrollment
25th of 34
82 · median 447
Started
2026
with 3 others
No phase
13 of 45
6 open now
Primary completion
2028-05
later than 10 of 16 live
Registered
44th of 45
by date

Among the 45 studies in Ischemic Stroke with a site in Netherlands, this one is the 25th largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 13 with no phase, reaches primary completion later than 10 of the 16 other live ones, and was the 44th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

14 of the 45 studies in Ischemic Stroke with a site in Netherlands are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Ischemic Stroke with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this randomized clinical trial is to evaluate whether continuous glucose monitoring (CGM) can be used to guide glucose management in patients with type 2 diabetes who are admitted with an acute ischemic stroke and undergo endovascular therapy. Hyperglycemia frequently occurs during hospitalization in stroke and is associated with worse neurological and clinical outcomes. In current clinical practice, glucose levels are monitored using intermittent point-of-care testing (POCT) with finger-prick measurements, which may miss clinically relevant glucose fluctuations. CGM provides continuous glucose measurements and may allow earlier detection of hyperglycemia and more timely glucose management.

This study is designed as a multicenter, non-inferiority randomized controlled trial comparing CGM-guided glucose management with standard POCT-guided glucose management in two stroke centers in the Netherlands. The primary objective is to determine whether CGM-guided glucose management is non-inferior to POCT-guided management in terms of percentage time spent in hyperglycemia (glucose >10 mmol/L) during the first 72 hours of hospitalization.

Researchers will compare CGM-guided glucose management to POCT-guided glucose management to evaluate whether CGM can be used as an alternative strategy to guide glucose control in hospitalized stroke patients.

Participants will:

  • Be randomly assigned to either CGM-guided glucose management or standard POCT-guided glucose management
  • Have their glucose levels continuously monitored (blinded in the POCT-guided group) during hospitalization
  • Receive glucose management according to the assigned monitoring strategy, based on a standardized insulin correction scheme applied uniformly across all participating centers
03

Conditions studied

  • Acute Ischemic Stroke
  • Diabetes (DM)
  • Diabetes Type 2
  • Hyperglycemia
  • Stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Acute ischemic stroke treated with endovascular therapy (EVT)
  • Type 2 diabetes mellitus, defined as one of the following:
  • documented diagnosis of type 2 diabetes mellitus
  • use of glucose-lowering medication
  • admission plasma glucose ≥11.1 mmol/L
  • ≥48 mmol/mol (≥6.5%)

Exclusion criteria

Exclusion Criteria:

  • Current pregnancy
  • Extensive skin infections or dermatological conditions at the intended sensor site
  • Medical situations known to interfere with CGM accuracy, including:
  • Hypotension defined as a systolic blood pressure \<100 mmHg at 30 and 60 minutes after admission
  • Dialysis treatment
  • Estimated (eGFR) \<15 mL/min/1.73 m²
  • Use of medications known to interfere with CGM accuracy, including:
  • Acetaminophen >4 g/day
  • Dopamine
  • High-dose vitamin C (ascorbic acid)
  • Hydroxyurea / hydroxycarbamide
  • pancreatic disease
  • Systemic therapy with a prednisone-equivalent dose >5 mg/day
  • Expected admission to an intensive care unit (ICU)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    CGM-guided glucose management

    Participants receive glucose monitoring using a continuous glucose monitoring (CGM) system (FreeStyle Libre 2). Glucose management during hospitalization is guided by CGM measurements and used for treatment decisions according to the hospital glucose management protocol.

    Device: Continuous Glucose Monitoring

  • Active comparator
    POCT-guided glucose management

    Participants receive standard glucose monitoring using intermittent point-of-care testing (POCT) with capillary finger-prick measurements. Glucose management during hospitalization follows the hospital glucose management protocol based on POCT values. A blinded continuous glucose monitoring sensor (FreeStyle Libre Pro iQ) is placed for data collection purposes only. CGM data are not available to the clinical team and are not used for treatment decisions.

    Diagnostic Test: Point-of-Care Testing

Interventions

  • DeviceContinuous Glucose Monitoring

    Continuous glucose monitoring using the FreeStyle Libre systems (Abbott Diabetes Care) to measure interstitial glucose levels through a subcutaneous sensor that continuously records glucose concentrations during hospitalization.

    Also known as: FreeStyle Libre 2, CGM

  • Diagnostic testPoint-of-Care Testing

    Intermittent glucose monitoring using point-of-care finger-prick capillary blood glucose measurements according to the hospital glucose management protocol.

    Also known as: POCT

06

What researchers measure

Primary outcomes

  1. Time spent in hyperglycemia (>10 mmol/L)

    Percentage of time during hospitalization with glucose levels above 10 mmol/L measured using continuous glucose monitoring.

    Time frame: During the first 72 hours of hospitalization

Secondary outcomes

  1. Duration of hyperlgycemic episodes (>10 mmol/L)

    Duration of hyperglycemic episodes (\>10 mmol/L) measured using continuous glucose monitoring.

    Time frame: During the first 72 hours of hospitalization

  2. Duration of hypoglycemic episodes (<3.9 mmol/L)

    Duration of hypoglycemic episodes (\<3.9 mmol/L) measured using continuous glucose monitoring.

    Time frame: During the first 72 hours of hospitalization

  3. Time in normoglycemia (3.9-10.0 mmol/L)

    Percentage of time with glucose levels between 3.9-10.0 mmol/L measured using continuous glucose monitoring.

    Time frame: During the first 72 hours of hospitalization

  4. Time in hypoglycemia (<3.9 mmol/L)

    Percentage of time with glucose levels \<3.9 mmol/L measured using continuous glucose monitoring

    Time frame: During the first 72 hours of hospitalization

  5. In-hospital complications

    Occurrence of in-hospital complications, including infection, symptomatic intracranial hemorrhage, and delirium during hospitalization.

    Time frame: During the first 72 hours of hospitalization

  6. Neurological recovery

    Neurological recovery assessed by change in National Institutes of Health Stroke Scale (NIHSS) score (range 0-42, higher scores indicate more severe neurological deficit) from baseline to 24 hours post-EVT. Early neurological improvement is defined as a ≥4-point decrease in NIHSS score, and major neurological improvement as a ≥8-point decrease or NIHSS ≤1.

    Time frame: Baseline to 24 hours post-EVT

  7. Good functional outcome

    Good functional outcome defined as a modified Rankin Scale (mRS) score ≤2 (range 0-6, lower scores indicate better functional outcome).

    Time frame: 3 months post stroke

  8. Health-related quality of life

    Health-related quality of life measured using the PROMIS-10 Global Health questionnaire (range 10-50, higher scores indicate better health-related quality of life).

    Time frame: 3 months post stroke

  9. All-cause mortality

    Time frame: 3 months post stroke

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2028, 25 months after the start.

Of 573 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 25 months is below that.

Counting every sponsor, half of 654 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 6, 2026
StartActual
Apr 21, 2026
Primary completionEst.
May 2028
CompletionEst.
Aug 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
2 sites added — first site in Netherlands
Show 2 added (2 Netherlands)
  • Medisch Spectrum Twente · Enschede, Netherlands
  • Isala Zwolle · Zwolle, Netherlands
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in Netherlands
    Show 2 added (2 Netherlands)
    • Medisch Spectrum Twente · Enschede, Netherlands
    • Isala Zwolle · Zwolle, Netherlands
    + 5 other changes: verification date, date precision, responsible party, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07510919
Lead sponsor
Isala
Collaborators
Medisch Spectrum Twente
Responsible party
Peter van Dijk (Principal Investigator, Internist-Endocrinologist, Isala) — Principal investigator
First posted
Apr 6, 2026
Start date
Apr 21, 2026
Primary completion
May 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Peter R van Dijk, MD PhD
Contact
p.r.van.dijk@isala.nl
+316 88 624 50 00

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion